Officer sold ~$1.01M of Eli Lilly
Scheduled in advanceTraded Oct 10, 2025 · Filed Oct 14, 2025
A big owner of Eli Lilly sold $2.75M of Eli Lilly shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$2,754,147
Shares × reported transaction price
64 days after results of Aug 7, 2025, 20 days before results of Oct 30, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $833.49 on Oct 10, 2025, 33% above its 52-week low and 11% below its high, after a 14% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $932.06 (Oct 11, 2024), 68% of the way up, from 250 adjusted closes. 30 trading days earlier: $731.96 on Aug 28, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Inluriyo on Sep 25, 2025, 15 days before this trade.
New drug application approved. Active ingredient: Imlunestrant Tosylate. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.7% | +0.4% | -2.1% |
| 30 days | +24.0% | +1.0% | +23.0% |
| 90 days | +30.3% | +4.3% | +26.0% |
| 180 days | +12.5% | +3.1% | +9.3% |
Past results only. Not a forecast.
Officer sold ~$1.01M of Eli Lilly
Scheduled in advance93.4M → 93.4M shares held
A big owner of Eli Lilly sold $830K of Eli Lilly shares. Nobody planned it ahead of time.
93.4M → 93.4M shares held
A big owner of Eli Lilly sold $7.61M of Eli Lilly shares. Nobody planned it ahead of time.